Quinten Health Recognized in the HealthTech 250

Quinten Health Recognized in the Prestigious HealthTech 250 by Galen Growth

We are thrilled to announce that Quinten Health has been officially selected for the HealthTech 250 (Europe 2026) cohort by Galen Growth. This recognition places us among the most promising and impactful digital health companies in the European ecosystem.

In their latest report, titled “Beyond the Hype,” Galen Growth identifies the startups delivering what they call a “real signal.” In an era where AI headlines are everywhere, this selection highlights companies built on solid clinical evidence, deep institutional partnerships, and genuine operational momentum rather than just media heat.

Delivering the “Real Signal” in Healthcare AI

At Quinten Health, providing a “real signal” is part of our DNA. While the industry often discusses the potential of Artificial Intelligence, we focus on the execution. Here is what sets our approach apart:

• 15+ Year “AI-Native” Heritage: We haven’t just joined the AI wave; we helped build it. Our long-standing expertise allows us to navigate the complexities of healthcare data with unmatched precision.
• Interpretable “Glass Box” Modeling: Unlike generic “black-box” AI, we emphasize transparency. Our approach provides actionable insights and explainable results, essential for regulatory-grade decision-making.
• Deep Regulatory & Institutional Integration: Our work is grounded in long-term partnerships with major institutions such as the EMA, FDA, C-Path, Inserm Transfert, Unicancer, and key consortia like More Europa and AIOLOS.
• Proven Impact: With over 500 projects delivered for 100+ life-science organizations, our impact is measured in real-world results, not just promises.

Our Commitment to “Validation-First” Innovation

Being part of the HealthTech 250 reinforces our commitment to a “Validation-First” philosophy. We don’t innovate for the sake of novelty; we innovate to solve the hardest problems in drug development and patient access.

By leveraging proprietary algorithms like Q-Finder for sub-population discovery and advanced Disease & Care Modeling, we continue to bridge the gap between data science and clinical reality. Our Evidence Operating System is designed to generate decision-grade evidence that accelerates drug development and patient access.

“At Quinten Health, we don’t just talk about the potential of AI; we deliver it. Our impact is measured in real-world results, backed by 34 scientific publications in the last 5 years.”

Read the full Galen Growth article to see how European digital health is driving real innovation.